These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24013033)

  • 1. A comparison of methods for classifying samples as truly specific with confirmatory immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Allacher P; Horling F
    J Pharm Biomed Anal; 2014 Jan; 88():27-35. PubMed ID: 24013033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Singer J; Allacher P; Horling F
    J Pharm Biomed Anal; 2011 Jul; 55(5):1148-56. PubMed ID: 21561734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?
    Jaki T; Allacher P; Horling F
    J Pharm Biomed Anal; 2016 Sep; 128():166-173. PubMed ID: 27262992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope characterization of the ADA response directed against a targeted immunocytokine.
    Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
    J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
    Li J; Schantz A; Schwegler M; Shankar G
    J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies.
    Partridge MA; Purushothama S; Elango C; Lu Y
    J Immunol Res; 2016; 2016():6262383. PubMed ID: 27556048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies.
    Geng D; Shankar G; Schantz A; Rajadhyaksha M; Davis H; Wagner C
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):364-75. PubMed ID: 15963677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay.
    Ray CA; Dumaual C; Willey M; Fill J; O'Brien PJ; Gourley I; Devanarayan V; Konrad RJ
    J Pharm Biomed Anal; 2006 Apr; 41(1):189-95. PubMed ID: 16321496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes.
    Shibata H; Nishimura K; Miyama C; Tada M; Suzuki T; Saito Y; Ishii-Watabe A
    J Immunol Methods; 2018 Jan; 452():73-77. PubMed ID: 28970009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of hepatitis B assays on the Bayer ADVIA Centaur Immunoassay System.
    van Helden J; Denoyel G; Karwowska S; Reamer R; Schmalz J; Wright T; Preisel-Simmons B
    Clin Lab; 2004; 50(1-2):63-73. PubMed ID: 15000222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
    J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA antibody detection and characterization by solid phase immunoassays: methods and pitfalls.
    Zachary AA; Vega RM; Lucas DP; Leffell MS
    Methods Mol Biol; 2012; 882():289-308. PubMed ID: 22665241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.
    Wessels U; Schick E; Ritter M; Kowalewsky F; Heinrich J; Stubenrauch K
    Bioanalysis; 2017 Jun; 9(11):849-859. PubMed ID: 28517957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.